The sustained intratumoral retention of the radiolabeled peptide supports its utility as a theranostic platform for both the molecular imaging and targeted radiopharmaceutical therapy of GPC3-expressing HCC. This evidence concerns the gene GPC3 and hepatocellular carcinoma.